You are here

HAE

Intellia links in vivo CRISPR therapy to 81% drop in HAE attacks in phase 2

Fierce Biotech

Thu, 10/24/24 - 09:58 am

Intellia Therapeutics

KalVista files first oral on-demand HAE drug with FDA

Pharmaphorum

Tue, 06/18/24 - 11:23 am

Ionis reveals an oasis for HAE patients as RNA med reduces attacks in phase 3

Fierce Biotech

Fri, 05/31/24 - 11:00 am

Ionis Pharmaceuticals

clinical trials

Intellia’s CRISPR drug could offer one-shot HAE treatment

Pharmaphorum

Thu, 02/1/24 - 11:26 am

Intellia Therapeutics

clinical trials

Ionis says rare disease drug succeeds in late-stage HAE study

BioPharma Dive

Mon, 01/22/24 - 11:10 am

Ionis Pharmaceuticals

clinical trials

Pharvaris' oral hereditary angioedema med slashes attacks in turnaround post-FDA hold

Fierce Biotech

Wed, 12/6/23 - 10:34 am

clinical trials

CRISPR on the Cusp: The Promise and the Pain Points

BioSpace

Mon, 07/10/23 - 09:27 pm

Intellia Therapeutics

Patients attack-free a year after receiving Intellia's hereditary angioedema CRISPR med

Fierce Biotech

Sun, 06/11/23 - 11:07 pm

Intellia Therapeutics

hereditary angiodema

CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing

Drugs.com

Wed, 03/1/23 - 10:07 am

clinical trials

Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting

Yahoo Finance

Sun, 11/13/22 - 06:59 pm

Ionis Pharmaceuticals

clinical trials

hereditary angiodema

Pharvaris studies of rare disease drug put on hold by FDA

BioPharma Dive

Mon, 08/22/22 - 08:12 pm

hereditary angiodema

CSL reports Phase III data for garadacimab to treat hereditary angioedema

Clinical Trials Arena

Thu, 08/18/22 - 12:30 pm

clinical trials

hereditary angiodema

Intellia doses first patient as hereditary angioedema gene editing therapy lands in clinic

Fierce Biotech

Mon, 12/13/21 - 11:46 pm

Intellia Therapeutics

clinical trials

Takeda, CSL hereditary angioedema meds need steep discounts following real-world evidence review, ICER says

Fierce Pharma

Wed, 08/25/21 - 09:32 pm

hereditary angiodema

BioCryst's persistence for patient insights leads to a bigger market for HAE drug Orladeyo

Fierce Pharma

Tue, 05/25/21 - 11:53 pm

Regulatory progress for two biotechs stalls as FDA requests more information

MedCity News

Wed, 04/21/21 - 10:30 am

Y-mAbs Therapeutics

FDA slaps a hold on KalVista's PhII study of an HAE drug, raising a red flag on preclinical results

Endpoints

Tue, 04/20/21 - 11:14 am

clinical trials

Mid-stage angioedema hit sends Kalvista though the roof

EP Vantage

Tue, 02/9/21 - 11:23 am

hereditary angiodema

BioCryst takes on Takeda, CSL with FDA approval for Orladeyo, the first pill to prevent HAE attacks

Fierce Pharma

Sat, 12/5/20 - 11:26 pm

Pharvaris lands another $80M as it looks to tackle Takeda and CSL with an oral approach for HAE

Endpoints

Wed, 11/18/20 - 11:07 pm

Pages